Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataset
Authors
Djebbari, FaouziRampotas, Alexandros
Vallance, Grant
Panitsas, Fotios
Basker, Nanda
Sangha, Gina
Salhan, Beena
Karim, Farheen
Al-Kaisi, Firas
Gudger, Amy
Ngu, Loretta
Poynton, Matt
Lam, Ho Pui Jeff
Morgan, Lowri
Yang, Laura
Young, Jennifer
Walker, Mairi
Tsagkaraki, Ismini
Anderson, Laura
Chauhan, Saleena Rani
Maddams, Rebecca
Soutar, Richard
Triantafillou, Margarita
Prideaux, Steve
Obeidalla, Abubaker
Bygrave, Ceri
Basu, Supratik

Ramasamy, Karthik
Issue Date
2022-05-30
Metadata
Show full item recordAbstract
Real-world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma (RRMM) patients have not been reported. In this UK-wide retrospective study, IsaPomDex outcomes were evaluated across 24 routine care cancer centres. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), duration of response (DOR) for patients who achieved an objective response (≥PR), and adverse events (AEs). In a total cohort 107 patients, median follow up (IQR) was 12.1 months (10.1-18.6 months), median age (IQR) was 69 years (61-77). Median (IQR) Charlson Co-morbidity index (CCI) score was 3 (2- 4); 43% had e-GFR<60 ml/min. Median (IQR) number of prior therapies was 3 (3-3). Median (IQR) number of IsaPomDex cycles administered was 7 (3-13). ORR was 66.4%, with responses categorised as ≥VGPR: 31.8%, PR: 34.6%, SD: 15.9%, PD: 15% and unknown 2.8%. Median PFS was 10.9 months. Median DOR was 10.3 months There was no statistical difference in median PFS by age (<65: 10.2 vs. 65-74 13.2 vs. ≥75: 8.5 months, log-rank p=0.4157), by CCI score (<4: 10.2 months vs. ≥4: 13.2, log-rank p=0.6531), but inferior PFS was observed with renal impairment (≥60: 13.2 vs. <60: 7.9 months, log-rank p=0.0408). Median OS was 18.8 months. After a median of 4 cycles, any grade AEs were experienced by 87.9% of patients. The most common ≥G3 AEs were neutropenia (45.8%), infections (18.7%) and thrombocytopenia (14%). Our UK-wide IsaPomDex study demonstrated encouraging efficacy outcomes in the real-world, comparable to ICARIA-MM trial.Citation
Djebbari, F., Rampotas, A., Vallance, G. et al. (2022) Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataset. HemaSphere, 6(6), e738.Publisher
Lippincott, Williams & WilkinsJournal
HemaSphereAdditional Links
https://journals.lww.com/hemasphere/pages/default.aspxType
Journal articleLanguage
enDescription
© 2022 The Authors. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: http://dx.doi.org/10.1097/HS9.0000000000000738ISSN
2572-9241ae974a485f413a2113503eed53cd6c53
10.1097/HS9.0000000000000738
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/